Show simple item record

dc.contributor.authorArrieta, O.
dc.contributor.authorRolfo, C.
dc.contributor.authorRuiz-Patiño, A.
dc.date.accessioned2019-12-25T18:07:12Z
dc.date.available2019-12-25T18:07:12Z
dc.date.issued2019
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85076407068&doi=10.1111%2f1759-7714.13272&partnerID=40&md5=a68a2de5bfacdb9dd4e6af98a6ea027a
dc.identifier.urihttp://hdl.handle.net/10713/11551
dc.description.abstractBackground: To compare survival outcomes of patients with advanced or metastatic non-small cell lung cancer (NSCLC) who received immunotherapy as first-, second- or beyond line, versus matched patients receiving standard chemotherapy with special characterization of hyperprogressors. Methods: A retrospective cohort study of 296 patients with unresectable/metastatic NSCLC treated with either, first-, second-, third- or fourth-line of immunotherapy was conducted. A matched comparison with a historical cohort of first-line chemotherapy and a random forest tree analysis to characterize hyperprogressors was conducted. Results: Median age was 64 years (range 34–90), 40.2% of patients were female. A total of 91.2% of patients had an Eastern Cooperative Oncology Group (ECOG) performance score ≤ 1. Immunotherapy as first-line was given to 39 patients (13.7%), second-line to 140 (48.8%), and as third-line and beyond to 108 (37.6%). Median overall survival was 12.7 months (95% CI 9.67–14 months) and progression-free survival (PFS) of 4.27 months (95% CI 3.97–5.0). Factors associated with increased survival included treatment with immunotherapy as first-line (P < 0.001), type of response (P < 0.001) and PD-L1 status (P = 0.0039). Compared with the historical cohort, immunotherapy proved to be superior in terms of OS (P = 0.05) but not PFS (P = 0.2). A total of 44 hyperprogressors were documented (19.8%, [95% CI 14.5–25.1%]). Leukocyte count over 5.300 cells/dL was present in both hyperprogressors and long-term responders. Conclusions: Patients who receive immune-checkpoint inhibitors as part of their treatment for NSCLC have better overall survival (OS) compared with matched patients treated with standard chemotherapy, regardless of the line of treatment. Copyright 2019 The Authors.en_US
dc.description.sponsorshipen_US
dc.description.urihttps://doi.org/10.1111/1759-7714.13272en_US
dc.language.isoen_USen_US
dc.publisherJohn Wiley and Sons Inc.en_US
dc.relation.ispartofThoracic Cancer
dc.subjectAdulten_US
dc.subjectimmunotherapyen_US
dc.subjectlung neoplasmsen_US
dc.subjectneoplasms/drug therapyen_US
dc.subjectprogrammed cell death 1 receptor/antagonists & inhibitorsen_US
dc.titleImmunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP)en_US
dc.typeArticleen_US
dc.identifier.doi10.1111/1759-7714.13272
dc.identifier.pmid31828967


This item appears in the following Collection(s)

Show simple item record